Congress Materials - American Association for Cancer Research (AACR 2024)
2024 American Association for Cancer Research | Apr 5-10 | San Diego, CA
This section includes selected Johnson & Johnson Innovative Medicine abstracts, posters, or oral presentations, which have been accepted for congress presentations in the last 2 years or less (as determined by any congress restrictions on length of time materials can be posted). Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. Johnson & Johnson does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling. The content contained in this section is subject to congress copyright permissions.
Amivantamab Efficacy in Wild-Type EGFR NSCLC Tumors Correlates with Levels of Ligand Expression
Ricardo Rivera-Soto, Benjamin Henley, Marian Pulgar, Stacey Lehman-Tenuto, Himanshu Gupta, Megan Weindorfer, Smruthi Vijayaraghavan, Tsun-Wen Sheena Yao, Sylvie Laquerre, Sheri Moores
Amivantamab in Wild-type Advanced Non-small Cell Lung Cancer (NSCLC) After Disease Progression on Checkpoint Inhibition and Chemotherapy: Results from the Phase 1b CHRYSALIS Study
Byoung Chul Cho, Jonathan Goldman, Natasha Leighl, Filippo De Braud, Ki Hyeong Lee, François Ghiringhelli, Pilar Garrido, Julio Peguero, Benjamin Besse, Phillippe Cassier, Nicolas Girard, Maria de Miguel, Rosa Alvarez, Alastair Greystoke, Yuchiro Ohe, Te-Chun Hsia, Joshua C. Curtin, Sanjib Chowdhury, Xuesong Lyu, Grace Gao, Siyang Qu, Patricia Lorenzini, Aastha Kapoor, Priya Kim, Mahadi Baig, Meena Thayu, Roland E. Knoblauch, Sandrine Hiret, Pascale Tomasini
Differential Preclinical Activity of Bruton Tyrosine Kinase Inhibitors Against BTK Resistance-Associated Mutations
Matthew S. Davids, Inhye E. Ahn, Jacob J. Riehm, Melih Acar, Vincent Girardi, Sima Patel, Elizabeth L. Noey, Tarikere Gururaja, Jennifer Woyach, Lloyd T. Lam, Edith Szafer-Glusman
Identification of Fibroblast Growth Factor Receptors (FGFRs) Alterations (Alts) at DNA and RNA-level by One-Step Next-Generation Sequencing
Min Qing, Xuejun Chen, Wenqing Su, Xiaofang Zhuo, Ting Shen, Chengjuan Xiong, Xuesong Lyu, Renee Tate, Qibiao Wu, Longen Zhou, Shibu Thomas, Wangwang Ning, Jianqing Wang, Huihui Yan, Ziqiang Yin, Zhan Huang, Yaxin Xue, Changbin Zhu
JNJ-87890387, A Novel ENPP3 Bispecific T-cell Redirector (ENPP3xCD3) with Tumor Selectivity Through Targeting Apical Surface Antigens
Smruthi Vijayaraghavan, Pankaj Seth, Annmarie Winkis, Kristen Chevalier, Alexa Marthaler, Katrin Sproesser, Vince Torti, Nirav Shah, Eilyn Lacy, Anna-Lena Frisk, Heather Deutsch, Gerald Chu, Michael Sharp, Jonathan Pabalan, Cholpon Tilegenova, Sitilia Rencheli, Katherine Thornton, Bethany Mattson, Ken Tian, Jacqueline Kinyamu-Akunda, Josh Lauring, Laurie Lenox, Wan Cheung Cheung, Sheri Moores, Sylvie Laquerre, Yusri Elsayed.
Molecular Subtyping and Immunohistochemistry Validation Identifies Muscle Invasive Bladder Cancer Subgroups With Poorer Overall Survival
Jiarui Zhang, Mingxiao Feng, Neil Beeharry, Shibu Thomas, Elke Veltrup, Ralph Wirtz, Arndt Hartmann, Markus Eckstein, Woonyoung Choi
Prevalence of Fibroblast Growth Factor Receptor (FGFR) Alterations and Programmed Death-Ligand 1 (PD-L1) Expression in Chinese Solid Tumor Patients
Min Qing, Fei Yang, Xiaowei Chen, Xuesong Lyu, Aodi Wang, Yanfei Yu, Shibu Thomas, Longen Zhou
Copies of these presentations are for personal use only and may not be reproduced without permission from the author of this presentation.